HIMS — Hims & Hers Health, Inc.

HIMS & HERS Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $608 million, up 4% year-over-year.
• Subscribers: Nearly 2.6 million, a 9% increase year-over-year.
• Adjusted EBITDA: $44 million, representing a 7% margin.
• International Revenue: Increased nearly tenfold to $78 million, driven by acquisitions.
• Net Income: Loss of $92 million, impacted by restructuring costs related to a strategic pivot in the weight loss specialty.
• Cash Flow: Generated $89 million from operations and $53 million in free cash flow.
• Balance Sheet: $751 million in cash and short-term investments, with $225 million remaining on the share repurchase program.

2. Strategic Updates and Business Highlights

• Strategic Pivot: Shifted focus in the weight loss specialty to branded products, resulting in the discontinuation of compounding products. This pivot aims to expand the addressable market and improve customer engagement.
• New Product Offerings: Successful introduction of Novo Nordisk's GLP-1 products, with over 125,000 shipments of Wegovy in six weeks.
• Global Expansion: Anticipated acquisition of Eucalyptus to enhance presence in Australia, the U.K., Germany, Japan, and Canada.
• Technology Investments: Continued investment in data and technology infrastructure to enhance customer experience and operational efficiency.
• AI Integration: Development of AI tools to improve customer interactions and care quality, including the Labs AI health care agent.

3. Forward Guidance and Outlook

• Q2 2026 Revenue Guidance: Expected between $680 million and $700 million, a year-over-year increase of 25% to 28%.
• Full-Year 2026 Revenue Outlook: Raised to $2.8 billion to $3 billion, representing a year-over-year increase of 19% to 28%.
• Adjusted EBITDA for 2026: Expected between $275 million and $350 million, with a margin of 11% at the midpoint.
• Long-Term Goals: Confidence in achieving 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

4. Bad News, Challenges, or Points of Concern

• Margin Compression: Anticipated gross margin decline due to the strategic pivot and the transition to shorter shipping cadences for branded products.
• Restructuring Costs: Approximately $33 million incurred due to the shift in the weight loss strategy, negatively impacting gross margins by about 5 points.
• GAAP Net Income Loss: Significant loss attributed to nonrecurring costs, raising concerns about profitability timelines.
• Volatility in Financial Metrics: Expected fluctuations in GAAP results and margins as the company navigates its strategic transition.

5. Notable Q&A Insights

• AI Development: Plans to create a multi-agent model to enhance customer care and outcomes, leveraging extensive data from patient interactions.
• Peptide Strategy: Focus on ensuring safety and quality before entering the peptide market, with a commitment to clinical oversight.
• Branded vs. Compounded Products: Transitioning to branded products has resulted in a significant increase in new customer acquisitions, indicating a successful strategic shift.
• International Growth: While the current focus is on U.S. operations, there is optimism for growth in international markets, particularly following the Eucalyptus acquisition.

Overall, Hims & Hers is navigating a strategic pivot that aims to enhance growth and customer engagement, despite facing challenges related to margin compression and restructuring costs. The company remains optimistic about its long-term goals and the potential for significant market expansion.